Market Overview

Jefferies & Company Maintains Auxilium Pharmaceuticals (AUXL) Buy Rating


Jefferies & Company analysts Thomas Wei, Shaunak Deepak and Thomas Nguyen rated shares of Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) a Buy, with a price target of $44.

The analysts said that like many biotech companies, Auxilium Pharmaceuticals, Inc is set to benefit greatly from health care reform.

Auxilium Pharmaceuticals' Xiaflex drug would receive an additional five years of patent protection under the new bill.

The additional profits of this move alone would add $10 per share to the analysts' price target for Auxilium Pharmaceuticals.

The Jefferies & Company analysts wrote, "the new health care reform act is a major positive for companies with biologics, as it creates a 12-year exclusivity period prior to biosimilar competition."

Posted-In: Auxilium Pharmaceuticals Jefferies & Company Shaunak Deepak Thomas Nguyen Thomas WeiAnalyst Color Price Target Analyst Ratings


Related Articles (AUXL)

View Comments and Join the Discussion!

Latest Ratings

TOLGoldman SachsInitiates Coverage On42.0
KBHGoldman SachsInitiates Coverage On36.0
YEXTSunTrust Robinson HumphreyMaintains28.0
LHCGSunTrust Robinson HumphreyMaintains160.0
DLRSunTrust Robinson HumphreyMaintains140.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Citigroup: Financial Winners & Losers (C, BAC)

3-22-10 Daily Small Cap Market News and Stock Highlights from